331 related articles for article (PubMed ID: 24035716)
21. Nucleophosmin gene mutations are predictors of favorable prognosis in acute myelogenous leukemia with a normal karyotype.
Schnittger S; Schoch C; Kern W; Mecucci C; Tschulik C; Martelli MF; Haferlach T; Hiddemann W; Falini B
Blood; 2005 Dec; 106(12):3733-9. PubMed ID: 16076867
[TBL] [Abstract][Full Text] [Related]
22. Immunohistochemistry predicts nucleophosmin (NPM) mutations in acute myeloid leukemia.
Falini B; Martelli MP; Bolli N; Bonasso R; Ghia E; Pallotta MT; Diverio D; Nicoletti I; Pacini R; Tabarrini A; Galletti BV; Mannucci R; Roti G; Rosati R; Specchia G; Liso A; Tiacci E; Alcalay M; Luzi L; Volorio S; Bernard L; Guarini A; Amadori S; Mandelli F; Pane F; Lo-Coco F; Saglio G; Pelicci PG; Martelli MF; Mecucci C
Blood; 2006 Sep; 108(6):1999-2005. PubMed ID: 16720834
[TBL] [Abstract][Full Text] [Related]
23. FLT3 and NPM1 mutations in myelodysplastic syndromes: Frequency and potential value for predicting progression to acute myeloid leukemia.
Bains A; Luthra R; Medeiros LJ; Zuo Z
Am J Clin Pathol; 2011 Jan; 135(1):62-9. PubMed ID: 21173125
[TBL] [Abstract][Full Text] [Related]
24. Nucleophosmin mutations confer an independent favorable prognostic impact in 869 pediatric patients with acute myeloid leukemia.
Xu LH; Fang JP; Liu YC; Jones AI; Chai L
Blood Cancer J; 2020 Jan; 10(1):1. PubMed ID: 31915364
[TBL] [Abstract][Full Text] [Related]
25. NPM1 alternative transcripts are upregulated in acute myeloid and lymphoblastic leukemia and their expression level affects patient outcome.
Handschuh L; Wojciechowski P; Kazmierczak M; Marcinkowska-Swojak M; Luczak M; Lewandowski K; Komarnicki M; Blazewicz J; Figlerowicz M; Kozlowski P
J Transl Med; 2018 Aug; 16(1):232. PubMed ID: 30126426
[TBL] [Abstract][Full Text] [Related]
26. Can cytoplasmic nucleophosmin be detected by immunocytochemical staining of cell smears in acute myeloid leukemia?
Mattsson G; Turner SH; Cordell J; Ferguson DJ; Schuh A; Grimwade LF; Bench AJ; Weinberg OK; Marafioti T; George TI; Arber DA; Erber WN; Mason DY
Haematologica; 2010 Apr; 95(4):670-3. PubMed ID: 20015883
[TBL] [Abstract][Full Text] [Related]
27. Prevalence and prognostic impact of NPM1 mutations in 1485 adult patients with acute myeloid leukemia (AML).
Thiede C; Koch S; Creutzig E; Steudel C; Illmer T; Schaich M; Ehninger G
Blood; 2006 May; 107(10):4011-20. PubMed ID: 16455956
[TBL] [Abstract][Full Text] [Related]
28. Immunohistochemical detection of cytoplasmic nucleophosmin in formalin-fixed paraffin-embedded marrow trephine biopsies in acute myeloid leukaemia.
Lit BM; Kwong YL; Wong KF
J Clin Pathol; 2016 May; 69(5):409-14. PubMed ID: 26500335
[TBL] [Abstract][Full Text] [Related]
29. [Detection of NPM1, FLT3 and C-KIT mutations in acute myeloid leukemia and their prognostic analysis].
Li L; Lyu XD; Mi RH; Ding J; Chen L; Wang Q; Yin QS; Hu JY; Fan RH; Wei XD
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2013 Jun; 21(3):601-6. PubMed ID: 23815906
[TBL] [Abstract][Full Text] [Related]
30. Pre-transplant Quantitative Determination of NPM1 Mutation Significantly Predicts Outcome of AIlogeneic Hematopoietic Stem Cell Transplantation in Patients with Normal Karyotype AML in Complete Remission.
Karas M; Steinerova K; Lysak D; Hrabetova M; Jungova A; Sramek J; Jindra P; Polivka J; Holubec L
Anticancer Res; 2016 Oct; 36(10):5487-5498. PubMed ID: 27798920
[TBL] [Abstract][Full Text] [Related]
31. Nucleophosmin (NPM1) mutations in adult and childhood acute myeloid leukaemia: towards definition of a new leukaemia entity.
Rau R; Brown P
Hematol Oncol; 2009 Dec; 27(4):171-81. PubMed ID: 19569254
[TBL] [Abstract][Full Text] [Related]
32. Trisomy 11 as an isolated abnormality in acute myeloid leukemia is associated with unfavorable prognosis but not with an NPM1 or KIT mutation.
Alseraye FM; Zuo Z; Bueso-Ramos C; Wang S; Medeiros LJ; Lu G
Int J Clin Exp Pathol; 2011 Apr; 4(4):371-7. PubMed ID: 21577323
[TBL] [Abstract][Full Text] [Related]
33. Multilineage dysplasia is associated with a poorer prognosis in patients with de novo acute myeloid leukemia with intermediate-risk cytogenetics and wild-type NPM1.
Rozman M; Navarro JT; Arenillas L; Aventín A; Giménez T; Alonso E; Perea G; Camós M; Navarrete M; Tuset E; Florensa L; Millá F; Nomdedéu J; de la Banda E; Díaz-Beyá M; Pratcorona M; Garrido A; Navarro B; Brunet S; Sierra J; Esteve J;
Ann Hematol; 2014 Oct; 93(10):1695-703. PubMed ID: 24824767
[TBL] [Abstract][Full Text] [Related]
34. Favorable outcome in patients with acute myelogenous leukemia with the nucleophosmin gene mutation autografted after conditioning with high-dose continuous infusion of idarubicin and busulfan.
Ferrara F; Izzo T; Criscuolo C; Riccardi C; Muccioli G; Viola A; Pane F; Palmieri S
Biol Blood Marrow Transplant; 2010 Jul; 16(7):1018-24. PubMed ID: 20172040
[TBL] [Abstract][Full Text] [Related]
35. Expression of CD4 is correlated with an unfavorable prognosis in wild-type NPM1, FLT3-ITD-negative cytogenetically normal adult acute myeloid leukemia.
Guo RJ; Atenafu EG; Schimmer AD; Minden MD; Chang H
Int J Lab Hematol; 2017 Aug; 39(4):429-437. PubMed ID: 28318150
[TBL] [Abstract][Full Text] [Related]
36. Clinical impact of nucleophosmin mutations and Flt3 internal tandem duplications in patients older than 60 yr with acute myeloid leukaemia.
Scholl S; Theuer C; Scheble V; Kunert C; Heller A; Mügge LO; Fricke HJ; Höffken K; Wedding U
Eur J Haematol; 2008 Mar; 80(3):208-15. PubMed ID: 18081718
[TBL] [Abstract][Full Text] [Related]
37. DNMT3A (R882) mutation features and prognostic effect in acute myeloid leukemia in Coexistent with NPM1 and FLT3 mutations.
Kumar D; Mehta A; Panigrahi MK; Nath S; Saikia KK
Hematol Oncol Stem Cell Ther; 2018 Jun; 11(2):82-89. PubMed ID: 29079128
[TBL] [Abstract][Full Text] [Related]
38. Prognostic significance of FLT3 internal tandem duplication and NPM1 mutations in acute myeloid leukemia in an unselected patient population.
Suzuki R; Onizuka M; Kojima M; Shimada M; Okamura K; Fukagawa S; Tsuboi K; Kikuchi A; Kobayashi H; Shintani A; Ogawa Y; Kawada H; Hotta T; Ando K
Int J Hematol; 2007 Dec; 86(5):422-8. PubMed ID: 18192111
[TBL] [Abstract][Full Text] [Related]
39. The effect of the detection of minimal residual disease for the prognosis and the choice of post-remission therapy of intermediate-risk acute myeloid leukemia without FLT3-ITD, NPM1 and biallelic CEBPA mutations.
Zheng WS; Hu YL; Guan LX; Peng B; Wang SY
Hematology; 2021 Dec; 26(1):179-185. PubMed ID: 33594943
[TBL] [Abstract][Full Text] [Related]
40. [NPM1 and CEBPA mutations in pediatric cytogenetically normal acute myeloid leukemia].
Ruan M; Zhang L; Han C; Liu X; Ai X; Zhang J; Liu T; Yang W; Chen X; Guo Y; Wang S; Li Q; Zou Y; Chen Y; Zhu X
Zhonghua Er Ke Za Zhi; 2014 Apr; 52(4):303-7. PubMed ID: 24915920
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
